Annual Report 2020-21
0% Annual Report Loaded
Annual Report 2020-21
We welcome and appreciate any constructive input and feedback from stakeholders.
Email
investors@glandpharma.com
Website
www.glandpharma.com
Annual Report 2020-21
We present the story of our past and an insight into our future. We intend to capture our strengths and strategies in our first post-IPO Annual Report. We are proud to present this report adopting the structure as described in the Integrated Reporting (IR) framework, as defined by the International Integrated Reporting Council (IIRC).
As our aim is to have a differentiated position in the industry, we are constantly challenging our limits and charting new frontiers of growth.
The capability to prosper amid altered circumstances define our core competencies and reflect our aspirations to fulfil organisational objectives.
We are a global injectables player with a single-minded focus on fulfilling diverse patient needs. In our continuous efforts to create value for patients, we are consistently improving our processes to deliver quality products. We are also expanding our R&D capabilities, improving our manufacturing facilities and foraying into diverse markets with a wide variety of products.
Million units of Finished Formulation Capacity 11,000 KG of Drug Substance (API) |
| + | Years of experience |
Employees as on March 31, 2021 |
Women Employees as on March 31, 2021 |
We operate in a competitive and highly-regulated industry. Our diversified portfolio allows us to respond to the opportunities and risks we face, while delivering value for all our stakeholders.
Value Creation Model
Our focus over the last four decades on building a quality first injectable company with a broad product portfolio and a differentiated business model has ensured sustained growth over the years.
